Pediatric Preclinical Testing Program (PPTP)
World-Renowned Biopathology Center
Clinical Trials
- At any given time there are a large number of clinical trials taking place at Children’s Hospital that offer state-of-the-art therapies and additional treatment options to your child.
- Learn more here »
Center for Childhood Cancer
The Center for Childhood Cancer's mission is to expand the understanding of the pathogenesis of childhood cancer and to improve strategies for diagnosis and treatment.
Areas of Focus
-
Biology and therapy of rhabdomyosarcoma and other childhood tumors
-
Chemotherapy of childhood solid tumors
-
Regulation of alternative pre-mRNA splicing
-
Regulation and function of tumor suppressor genes
-
Oncolytic viral therapy in pediatric brain tumors
Affiliations and Collaborations
Center for Childhood Cancer News
It May Be Clinically Acceptable to Delay Growth Factor Treatment in Children Post-Chemotherapy
Treating children with growth factors as late as five days after they receive a bone marrow or blood stem cell transplant may result in substantial cost savings and still be as clinically beneficial as treating patients one day after transplantation. These findings are from a Nationwide Children’s Hospital study appearing in Pediatric Blood & Cancer, the first study to examine whether delayed administration in pediatrics affects engraftment time.
Modified Measles Virus Shows Potential for Treating Childhood Brain Tumors
The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology. Medulloblastoma is the most common malignant central nervous system tumor of childhood, accounting for about 20 percent of pediatric brain tumors.
Quality of Life Plays Important but Neglected Role in Comparing Treatment for Severe Sickle Cell Disease
A study appearing in the Journal of Pediatric Hematology/Oncology suggests that stem cell transplantation may provide severe sickle cell patients with the greatest quality of life, but more data is needed before a “gold standard” treatment can be identified.
Combining Rapamycin with Chemotherapeutic Agents to Enhance Treatment of Childhood Cancer Appears Promising
Rapamycin, an immunosuppressant drug commonly used to prevent rejection in organ transplantation, has shown potential to inhibit tumor growth in many childhood cancers during in vitro and in vivo laboratory studies.
Nationwide Children's Hospital Selected as Biospecimen Core Resource for The Cancer Genome Atlas
Cancer/Gene Therapy Study Ranked as Top 10 Key Research in 2009
The paper details a promising new cancer-stopping therapy. The researchers discovered that delivering microRNAs, small molecules that are highly expressed in normal tissues but lost in diseased cells, can result in tumor suppression.
